Latest Hansa Biopharma News & Updates

See the latest news and media coverage for Hansa Biopharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Hansa Biopharma

Developer of immunomodulatory treatments for rare immunological diseases

hansabiopharma.com

Headquarters: Lund, Sweden
Founded year: 2007
Company type: Public company
Number of employees: 125–200

Last updated Today

Latest news about Hansa Biopharma

In short: Hansa Biopharma licensed Idefirix to SERB for €115 million, received an FDA PDUFA date for imlifidase, and reported mixed Phase 3 trial results.

Company announcements

June 15 Hansa Biopharma

Hansa Biopharma appoints Adam Cutler as CFO

He succeeds retiring Evan Ballantyne, effective June 22, 2026.

June 1 Hansa Biopharma

Hansa Biopharma holds Annual General Meeting and approves resolutions

The meeting re-elected directors, set board fees, and adopted long-term incentive programs for board and employees.

May 27 Hansa Biopharma

Hansa Biopharma reports positive results from Idefirix post-authorization study

The one-year graft failure-free survival was 90%, supporting full marketing authorization submission. Safety was consistent with prior trials.

May 19 Hansa Biopharma

Hansa Biopharma enters €115 million licensing agreement with SERB

The agreement covers Europe and MENA regions, with an upfront payment of €110 million, strengthening Hansa's financial position.

Media coverage

June 5 wallstreet:online

Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation

Nachrichten zur Vonovia Hansa Biopharma Aktie - Aktuelle Meldungen - Das sind die Expertenmeinungen des Monats Juni...

May 27 Yahoo

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from graft versus host disease (GvHD) in patients ...

May 22 ConSalud.es

SERB Pharmaceuticals acquires rights to Idefirix from Hansa Biopharma for €115 million | Salud35

The deal with Hansa Biopharma will allow SERB to take over the development and commercialization of the treatment in Europe, the United Kingdom and the MENA region for patients...

May 19 Dagens industri

Stock exchange opens upward - Hansa Biopharma surges

The Stockholm Stock Exchange starts Tuesday upward. Nibe, which had the heaviest report of the morning, declines. Hansa Biopharma surges on a new licensing agreement.

Never miss news about Hansa Biopharma

Track Hansa Biopharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.